A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

by Kirill V. Lepik, Liudmila V. Fedorova, Elena V. Kondakova, Yuri R. Zalyalov, Elena V. Babenko, Elena E. Lepik, Polina V. Kotselyabina, Anastasia V. Beynarovich, Marina O. Popova, Nikita P. Volkov, Lilia V. Stelmakh, Vadim V. Baykov, Ivan S. Moiseev, Natalia B. Mikhailova, Alexander D. Kulagin, Boris V. Afanasyev
Published 2020-10-01